Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21163146 | 0.95 | PDK2 (0.46) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21163145 | 0.94 | PDK2 (0.45) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21114117 | 0.93 | PDK2 (0.45) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21114178 | 0.92 | PDK2 (0.44) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21113990 | 0.92 | PDK2 (0.44) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21163140 | 0.91 | PDK2 (0.51) | PDK2BACE1BACE2GPR119USP30 | |
| SCHEMBL21113938 | 0.88 | KDM4E (0.39) | PDK2RARARARBTDP1LSS | |
| SCHEMBL2132598 | 0.84 | PDK2 (0.43) | PDK2BACE1BACE2USP30AAK1 | |
| SCHEMBL21114036 | 0.82 | KDM4E (0.40) | PDK2TDP1KDM4EALDH1A1 | |
| SCHEMBL21114079 | 0.81 | KDM4E (0.38) | PDK2RARARARBTDP1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | PDK2 3088/4885BACE1 3705/4885BACE2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.